Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399996 | 0.76 | AURKA (0.63) | AURKAAURKBCCNE1CDK2CDK5 | |
| SCHEMBL759855 | 0.74 | AURKA (0.75) | AURKAAURKB | |
| SCHEMBL13632595 | 0.72 | AURKA (0.38) | AURKALMNAMEN1HTTKMT2A | |
| SCHEMBL763184 | 0.70 | AURKA (0.52) | AURKAAURKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL764302 | 0.66 | FPR2 (0.43) | AURKANPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL759962 | 0.66 | AURKA (0.76) | AURKAAURKB | |
| SCHEMBL763075 | 0.66 | AURKA (0.63) | AURKAAURKB | |
| SCHEMBL13399912 | 0.65 | AURKA (0.52) | AURKAAURKB | |
| SCHEMBL756778 | 0.65 | AURKA (0.74) | AURKAAURKB | |
| SCHEMBL13399829 | 0.65 | AURKA (0.64) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | AURKA 2/4885AURKB 1/4885CCNE1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.